Tack 2009.

Methods	Randomised, double‐blind, placebo‐controlled trial. Multi‐centre (8). Criteria for FD: Rome II with both type of FD
Participants	N = 71 Female: 54% Mean age: 40 years for the prokinetic group and 49.1 years for the placebo group Countries: Belgium, the Netherlands, UK, Norway, Poland
Interventions	Intervention: acotiamide 50 mg, 100 mg and 300 mg three times a day Comparator: placebo Rescue medication: not mentioned Duration of treatment: 3 weeks
Outcomes	Participants assessed the severity (0 = absent; 1 = mild; 2 = moderate; 3 = severe) and the frequency (0 = absent; 1 = rarely; 2 = occasionally; 3 = often; 4 = whole day) of nine dyspeptic symptoms (upper abdominal pain, upper abdominal discomfort, postprandial fullness, upper abdominal bloating, early satiety, nausea, vomiting, excessive belching and heartburn). An overall symptom score was calculated as the sum of the mean weekly individual symptom scores.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised
Allocation concealment (selection bias)	Unclear risk	No information
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessed by patient who was blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	13% were excluded from the efficacy analysis but unbalance in each group.
Selective reporting (reporting bias)	Low risk	Reported all pre‐defined outcomes
Other bias	Unclear risk	Imbalance in age and gender, although did not reach statistical significance